{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:22:15Z","timestamp":1792678935257,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.cmi.2016.12.002","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T17:45:59Z","timestamp":1481391959000},"page":"234-241","source":"Crossref","is-referenced-by-count":37,"title":["Fluoroquinolones or macrolides in combination with \u03b2-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"23","author":[{"given":"K.Z.","family":"Vardakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.K.","family":"Trigkidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Falagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2016.12.002_bib1","series-title":"Update on 2004 Background Paper","author":"Tong","year":"2013"},{"key":"10.1016\/j.cmi.2016.12.002_bib2","first-page":"494","article-title":"The incidence rate and economic burden of community-acquired pneumonia in a working-age population","volume":"6","author":"Broulette","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.cmi.2016.12.002_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3810\/pgm.2010.03.2130","article-title":"Burden of community-acquired pneumonia in North American adults","volume":"122","author":"File","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.2016.0115","article-title":"Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review","volume":"315","author":"Lee","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2016.12.002_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0029-1243910","volume":"64","author":"Hoffken","year":"2010","journal-title":"Pneumologie"},{"issue":"Suppl 3","key":"10.1016\/j.cmi.2016.12.002_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"issue":"Suppl 2","key":"10.1016\/j.cmi.2016.12.002_bib7","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.002_bib8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3109\/00365548.2012.700120","article-title":"Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults\u2013Swedish Society of Infectious Diseases 2012","volume":"44","author":"Spindler","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.002_bib9","first-page":"90","article-title":"SWAB\/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults","volume":"70","author":"Wiersinga","year":"2012","journal-title":"Neth J Med"},{"issue":"Suppl 6","key":"10.1016\/j.cmi.2016.12.002_bib10","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections\u2013full version","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2016.12.002_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.idc.2004.04.010","article-title":"Macrolides and ketolides: azithromycin, clarithromycin, telithromycin","volume":"18","author":"Zuckerman","year":"2004","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.cmi.2016.12.002_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1579-2129(11)60008-6","article-title":"Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR)","volume":"46","author":"Menendez","year":"2010","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.cmi.2016.12.002_bib13","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"beta-Lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib14","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","article-title":"Antibiotic treatment strategies for community-acquired pneumonia in adults","volume":"372","author":"Postma","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1503\/cmaj.080358","article-title":"Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials","volume":"179","author":"Vardakas Siempos","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.cmi.2016.12.002_bib16","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jamainternmed.2014.3996","article-title":"The debate on antibiotic therapy for patients hospitalized for pneumonia: where should we go from here?","volume":"174","author":"Lee","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib17","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dku033","article-title":"beta-Lactam\/macrolide dual therapy versus beta-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis","volume":"69","author":"Nie","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.12.002_bib18","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1086\/587519","article-title":"Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study\u2013a randomized clinical trial","volume":"46","author":"Torres","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.002_bib19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"Infectious Society of America","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.cmi.2016.12.002_bib21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2016.12.002_bib22","unstructured":"Effect estimates and generic inverse variance meta-analysis. Available at: http:\/\/handbook.cochrane.org\/chapter_7\/7_7_7_1_effect_estimates_and_generic_inverse_variance.htm."},{"key":"10.1016\/j.cmi.2016.12.002_bib23","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jac\/dks065","article-title":"Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis","volume":"67","author":"Rottier","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.12.002_bib24","doi-asserted-by":"crossref","first-page":"R265","DOI":"10.1186\/cc13095","article-title":"Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance","volume":"17","author":"Adrie","year":"2013","journal-title":"Crit Care"},{"issue":"Suppl 3","key":"10.1016\/j.cmi.2016.12.002_bib25","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1086\/591404","article-title":"Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project","volume":"47","author":"Bratzler","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.002_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1157\/13075996","article-title":"Patients hospitalized with community-acquired pneumonia: a comparative study of outcomes by medical specialty area","volume":"41","author":"Capelastegui","year":"2005","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.cmi.2016.12.002_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1157\/13089540","article-title":"Evaluation of clinical practice in patients admitted with community-acquired pneumonia over a 4-year period","volume":"42","author":"Capelastegui","year":"2006","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.cmi.2016.12.002_bib28","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1086\/586749","article-title":"The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy","volume":"46","author":"Charles","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.002_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.amjmed.2006.02.014","article-title":"Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia","volume":"119","author":"Frei","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib30","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1378\/chest.119.5.1420","article-title":"Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states : 1993, 1995, and 1997","volume":"119","author":"Houck","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2016.12.002_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/aas.12081","article-title":"Severe community-acquired pneumonia treated with beta-lactam-respiratory quinolone vs. beta-lactam-macrolide combination","volume":"57","author":"Karhu","year":"2013","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.cmi.2016.12.002_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12890-015-0108-x","article-title":"Real life management of community-acquired Pneumonia in adults in the Gulf region and comparison with practice guidelines: a prospective study","volume":"15","author":"Mahboub","year":"2015","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","article-title":"Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia","volume":"36","author":"Martin-Loeches","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00188710","article-title":"Initial management of pneumonia and sepsis: factors associated with improved outcome","volume":"39","author":"Menendez","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2016.12.002_bib35","first-page":"245","article-title":"Management of Community-Acquired Pneumonia at a Tertiary-Care Teaching Hospital","volume":"60","author":"Minhas","year":"2007","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.cmi.2016.12.002_bib36","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/cc11471","article-title":"Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study","volume":"16","author":"Mongardon","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2016.12.002_bib37","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/cc3934","article-title":"The impact of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia","volume":"10","author":"Mortensen","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2016.12.002_bib38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/thoraxjnl-2012-203106","article-title":"Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia","volume":"68","author":"Naucler","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.cmi.2016.12.002_bib39","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/archinte.161.15.1837","article-title":"Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia","volume":"161","author":"Waterer","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib40","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1097\/CCM.0b013e31825151a8","article-title":"Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia","volume":"40","author":"Wilson","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2016.12.002_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2016.12.002_bib43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1378\/chest.128.1.172","article-title":"Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors","volume":"128","author":"Leroy","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2016.12.002_bib44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects","volume":"450","author":"Culic","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cmi.2016.12.002_bib45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.qco.0000160901.71813.fe","article-title":"Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections","volume":"18","author":"Parnham","year":"2005","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.002_bib46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1473-3099(03)00658-3","article-title":"Immunomodulatory effects of quinolones","volume":"3","author":"Dalhoff","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.002_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/cc3976","article-title":"Choosing the right combination therapy in severe community-acquired pneumonia","volume":"10","author":"Waterer","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2016.12.002_bib48","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/jac\/dki251","article-title":"Differential effects of three antibiotics on T helper cell cytokine expression","volume":"56","author":"Williams","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.12.002_bib49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.002_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2015.04.010","article-title":"Fluoroquinolones or macrolides alone versus combined with beta-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis","volume":"46","author":"Raz-Pasteur","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2016.12.002_bib51","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jac\/dkr016","article-title":"Comparative evaluation of synergy of combinations of beta-lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniae","volume":"66","author":"Drago","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.12.002_bib52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijantimicag.2012.12.006","article-title":"beta-Lactam plus aminoglycoside or fluoroquinolone combination versus beta-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis","volume":"41","author":"Vardakas","year":"2013","journal-title":"Int J Antimicrob Agents"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16306073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16306073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T02:50:59Z","timestamp":1536202259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X16306073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1198743X16306073"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.12.002","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}